Report Includes:

  • An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
  • Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
  • Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
  • Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
  • Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications